Smaller trials and more post-marketing surveillance could speed drugs from 'bench to bedside'
This article was originally published in SRA
Executive Summary
The development costs for drugs could be slashed by as much as 90% and the time required to get new medicines "from bench to bedside" cut by half if the thresholds of approval were changed to look just at efficacy and fundamental safety, according to two senior venture capitalists writing in the New England Journal of Medicine.